The pharmaceutical market of medicines containing retinoids for the treatment of psoriasis in Ukraine, Poland and Kazakhstan

Authors

DOI:

https://doi.org/10.15587/2519-4852.2023.274776

Keywords:

retinoids, psoriasis, pharmaceutical market analysis, drug register

Abstract

The aim of the work is to analyze the use of medicines containing retinoids for the treatment of psoriasis on the example of Ukraine, Poland and Kazakhstan.

Materials and methods. The object of the study was antipsoriatic drugs, which are used for the treatment of psoriasis of local and systemic action, and are included in the official register of drugs of the studied countries. Regulatory documents of the State Expert Center of the Ministry of Health of Ukraine were involved in the analysis of the use of medicines for the treatment of psoriasis in Ukraine.

The analysis of the availability of the considered medicines on pharmaceutical markets was carried out according to the data of the official websites of the State Register of Medicines (Ukraine), the Register of Medicines of Poland (Republic of Poland), data of the National Center for Expertise of Medicines and Medical Devices of the Republic of Kazakhstan (Republic of Kazakhstan).

The following methods of logical and meaningful formulation of the problem, office marketing research, content analysis of publications in scientific and practically oriented medical and pharmaceutical publications, comparative analysis, tabular and graphic means of visual presentation of the obtained data were used in the work.

The results. According to the results of the obtained data, an assortment of medicinal products containing retinoids of the studied countries, used for the treatment of psoriasis, was determined. The fate of domestic production in the countries was analyzed, the main active components from the group of retinoids used for the treatment of psoriasis in preparations of systemic and local action were updated.

Conclusions. The role of retinoids in the treatment of psoriasis in Ukraine, Poland and Kazakhstan and the need to develop modern domestic medicines containing retinoids for the treatment of psoriasis have been determined

Author Biographies

Oksana Shtrimaitis, Municipal Institution of Higher Education "Rivne Medical Academy" of Rivne Region Council

PhD

Department of Chemical and Pharmaceutical Disciplines

Oleksandr Kukhtenko, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor

Department of Pharmaceutical of Technologies

Olga Sadovnyk, Municipal Institution of Higher Education "Rivne Medical Academy" of Rivne Region Council

PhD

Department of Chemical and Pharmaceutical Disciplines

Halyna Kukhtenko, National University of Pharmacy

PhD, Associate Professor

Department of Cosmetology and Aromology

References

  1. Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., Barker, J. N. W. N. (2021). Psoriasis. The Lancet, 397 (10281), 1301–1315. doi: https://doi.org/10.1016/s0140-6736(20)32549-6
  2. Global report on psoriasis (2016). Geneva: World Health Organization. Available at: https://apps.who.int/iris/handle/10665/204417
  3. Kamiya, K., Kishimoto, M., Sugai, J., Komine, M., Ohtsuki, M. (2019). Risk Factors for the Development of Psoriasis. International Journal of Molecular Sciences, 20 (18), 4347. doi: https://doi.org/10.3390/ijms20184347
  4. Rendon, A., Schäkel, K. (2019). Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences, 20 (6), 1475. doi: https://doi.org/10.3390/ijms20061475
  5. Griffiths, C. E., Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370 (9583), 263–271. doi: https://doi.org/10.1016/s0140-6736(07)61128-3
  6. Kotvitckaia, A. A., Karlo, V. V. (2013). Marketingovyi analiz assortimenta rynka lekarstvennykh preparatov, primeniaemykh dlia lecheniia psoriaza v Ukraine. Problemy sotcialnoi gigieny, zdravookhraneniia i istorii meditciny, 3, 50–53.
  7. Psoriaz, vkliuchaiuchy psoriatychni artropatii. Adaptovana klinichna nastanova, zasnovana na dokazakh (2015). Kyiv, 223.
  8. Derzhavnyi Ekspertnyi tsentr MOZ Ukrainy. Psoriaz. Available at: https://www.dec.gov.ua/mtd/psoriaz/
  9. Gollnick, H., Menter, A. (1999). Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. British Journal of Dermatology, 140 (S54), 18–23. doi: https://doi.org/10.1046/j.1365-2133.1999.140s54018.x
  10. Green, L., Sadoff, W. (2002). A clinical evaluation of tazarotene 0.1 % gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology, 6 (2), 95–102. doi: https://doi.org/10.1007/s10227-001-0031-z
  11. Youssef, R. M., Mahgoub, D., Mashaly, H. M., El-Nabarawy, E., Samir, N., El-Mofty, M. (2008). Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study. Photodermatology, Photoimmunology & Photomedicine, 24 (5), 256–259. doi: https://doi.org/10.1111/j.1600-0781.2008.00371.x
  12. Shtrimaitis, O. V., Kukhtenko, O. S., Chuieshov, V. I. (2022). Marketing analysis of the use of drugs containing retinoids in the treatment of acne. Farmatsevtychnyi Zhurnal, 6, 3–10. doi: https://doi.org/10.32352/0367-3057.6.22.01
  13. Baldwin, H., Webster, G., Stein Gold, L., Callender, V., Cook-Bolden, F. E., Guenin, E. (2021). 50 Years of Topical Retinoids for Acne: Evolution of Treatment. American Journal of Clinical Dermatology, 22 (3), 315–327. doi: https://doi.org/10.1007/s40257-021-00594-8
  14. Nadal, J. M., dos Anjos Camargo, G., Novatski, A., Macenhan, W. R., Dias, D. T., Barboza, F. M. et al. (2019). Adapalene-loaded poly(ε-caprolactone) microparticles: Physicochemical characterization and in vitro penetration by photoacoustic spectroscopy. PLOS ONE, 14 (3), e0213625. doi: https://doi.org/10.1371/journal.pone.0213625
  15. Kircik, L. H., Draelos, Z. D., Berson, D. S. (2019). Polymeric Emulsion Technology Applied to Tretinoin. Journal of Drugs in Dermatology, 18 (4), 148–154.
  16. Zhang, Y., Wischke, C., Mittal, S., Mitra, A., Schwendeman, S. P. (2016). Design of Controlled Release PLGA Microspheres for Hydrophobic Fenretinide. Molecular Pharmaceutics, 13 (8), 2622–2630. doi: https://doi.org/10.1021/acs.molpharmaceut.5b00961
  17. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: https://cutt.ly/jJ2S3i6
  18. Kompendium. Likarski preparaty. Available at: https://compendium.com.ua/uk/
  19. Derzhavnyi formuliar likarskykh zasobiv (2019). Kyiv, 1186.
  20. Reiestr likarskykh zasobiv Polshchi (Polshcha). Available at: https://rejestrymedyczne.ezdrowie.gov.pl/rpl/search/public
  21. National Center for Examination of Medicines and Medical Devices of the Republic of Kazakhstan (Kazakhstan). Available at: http://register.ndda.kz/
  22. Chu, S., Michelle, L., Ekelem, C., Sung, C. T., Rojek, N., Mesinkovska, N. A. (2020). Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions. Archives of Dermatological Research, 313 (6), 391–430. doi: https://doi.org/10.1007/s00403-020-02152-4
  23. Daulatabad, D., Grover, C. (2022). Topical tretinoin in the treatment of nail psoriasis. Indian Dermatology Online Journal, 13 (1), 126–127. doi: https://doi.org/10.4103/idoj.idoj_222_21
  24. Kaidbey, K. H., Petrozzi, J. W., Kligman, A. M. (1975). Treatment of psoriasis with topically applied tretinoin and steroid ointment. Archives of Dermatology, 111 (8), 1001–1003. doi: https://doi.org/10.1001/archderm.1975.01630200061006
  25. Milosheska, D., Roškar, R. (2022). Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations. Advances in Therapy, 39 (12), 5351–5375. doi: https://doi.org/10.1007/s12325-022-02319-7
  26. Halioua, B., Saurat, J.-H. (1990). Risk:benefit ratio in the treatment of psoriasis with systemic retinoids. British Journal of Dermatology, 122 (s36), 135–150. doi: https://doi.org/10.1111/j.1365-2133.1990.tb02891.x
  27. Orfanos, C. E. (1999). Treatment of psoriasis with retinoids: present status. Cutis, 64 (5), 347–353.

Downloads

Published

2023-02-28

How to Cite

Shtrimaitis, O., Kukhtenko, O., Sadovnyk, O., & Kukhtenko, H. (2023). The pharmaceutical market of medicines containing retinoids for the treatment of psoriasis in Ukraine, Poland and Kazakhstan. ScienceRise: Pharmaceutical Science, (1(41), 50–57. https://doi.org/10.15587/2519-4852.2023.274776

Issue

No. 1(41) (2023)

Section

Pharmaceutical Science

License

Copyright (c) 2023 Oksana Shtrimaitis, Oleksandr Kukhtenko, Olga Sadovnyk, Halyna Kukhtenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons Attribution 4.0 International License copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.

3. Authors have the right to store the final accepted version of the article in an institutional, thematic, or any other repository to ensure visibility and accessibility.